---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-18T22:35:38.973258'
end_time: '2026-01-18T22:42:05.730730'
duration_seconds: 386.76
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: LRRK2
  gene_symbol: LRRK2
  uniprot_accession: Q5S007
  protein_description: 'RecName: Full=Leucine-rich repeat serine/threonine-protein
    kinase 2; EC=2.7.11.1 {ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:28720718,
    ECO:0000269|PubMed:29125462, ECO:0000269|PubMed:29127255, ECO:0000269|PubMed:29212815,
    ECO:0000269|PubMed:30398148, ECO:0000269|PubMed:30635421}; EC=3.6.5.- {ECO:0000269|PubMed:18230735,
    ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:28720718, ECO:0000269|PubMed:29125462,
    ECO:0000269|PubMed:29212815}; AltName: Full=Dardarin;'
  gene_info: Name=LRRK2; Synonyms=PARK8;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the protein kinase superfamily. TKL Ser/Thr
  protein_domains: ANK_LRRK2. (IPR056593); Ankyrin_rpt-contain_sf. (IPR036770); ARM-like.
    (IPR011989); ARM-type_fold. (IPR016024); ARM_LRRK2. (IPR056597)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 21
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q5S007
- **Protein Description:** RecName: Full=Leucine-rich repeat serine/threonine-protein kinase 2; EC=2.7.11.1 {ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:28720718, ECO:0000269|PubMed:29125462, ECO:0000269|PubMed:29127255, ECO:0000269|PubMed:29212815, ECO:0000269|PubMed:30398148, ECO:0000269|PubMed:30635421}; EC=3.6.5.- {ECO:0000269|PubMed:18230735, ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:28720718, ECO:0000269|PubMed:29125462, ECO:0000269|PubMed:29212815}; AltName: Full=Dardarin;
- **Gene Information:** Name=LRRK2; Synonyms=PARK8;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the protein kinase superfamily. TKL Ser/Thr
- **Key Domains:** ANK_LRRK2. (IPR056593); Ankyrin_rpt-contain_sf. (IPR036770); ARM-like. (IPR011989); ARM-type_fold. (IPR016024); ARM_LRRK2. (IPR056597)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "LRRK2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'LRRK2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **LRRK2** (gene ID: LRRK2, UniProt: Q5S007) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q5S007
- **Protein Description:** RecName: Full=Leucine-rich repeat serine/threonine-protein kinase 2; EC=2.7.11.1 {ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:28720718, ECO:0000269|PubMed:29125462, ECO:0000269|PubMed:29127255, ECO:0000269|PubMed:29212815, ECO:0000269|PubMed:30398148, ECO:0000269|PubMed:30635421}; EC=3.6.5.- {ECO:0000269|PubMed:18230735, ECO:0000269|PubMed:26824392, ECO:0000269|PubMed:28720718, ECO:0000269|PubMed:29125462, ECO:0000269|PubMed:29212815}; AltName: Full=Dardarin;
- **Gene Information:** Name=LRRK2; Synonyms=PARK8;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the protein kinase superfamily. TKL Ser/Thr
- **Key Domains:** ANK_LRRK2. (IPR056593); Ankyrin_rpt-contain_sf. (IPR036770); ARM-like. (IPR011989); ARM-type_fold. (IPR016024); ARM_LRRK2. (IPR056597)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "LRRK2" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'LRRK2' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **LRRK2** (gene ID: LRRK2, UniProt: Q5S007) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan status and verification
- Target identity verification: The report focuses on human LRRK2 (UniProt Q5S007), also known as dardarin/PARK8. Literature and structural studies consistently describe a large ROCO-family protein with N‑terminal ARM/ANK/LRR repeats, a central ROC (GTPase) and COR tandem, followed by a Ser/Thr kinase domain and C‑terminal WD40 domain. Dual catalytic activities—protein kinase (EC 2.7.11.1) and ROC GTPase (EC 3.6.5.-)—are well established (gilsbach2024intramolecularfeedbackregulation pages 16-17, dzamko2025leucinerichrepeatkinase pages 9-10).

Key concepts and definitions (current understanding)
- Structure and domains: LRRK2 is a multi-domain ROCO protein with ARM/ANK/LRR–ROC–COR–kinase–WD40 architecture. The ROC-COR tandem regulates the kinase; interdomain cross-talk shapes activation state and oligomerization (e.g., dimerization) (gilsbach2024intramolecularfeedbackregulation pages 16-17). 14‑3‑3 proteins bind phosphorylated sites in the N‑terminus (Ser910/Ser935 cluster), stabilizing an inactive state (dzamko2025leucinerichrepeatkinase pages 9-10).
- Catalytic activities: LRRK2 is a Ser/Thr kinase and a small GTPase (ROC). Intramolecular feedback regulates the ROC GTPase by kinase-dependent autophosphorylation (e.g., ROC P‑loop T1343) affecting GTPase kinetics and monomer–dimer equilibrium (gilsbach2024intramolecularfeedbackregulation pages 16-17). Autophosphorylation at Ser1292 is a readout of kinase activity (dzamko2025leucinerichrepeatkinase pages 9-10).
- Primary substrates and substrate specificity: Phosphoproteomics and targeted studies define a subset of Rab GTPases as primary physiologic substrates, with Rab10 Thr73 the prototypic site; additional validated Rabs include Rab8A/B, Rab12, Rab29, Rab35, Rab43. Phospho‑Rab readouts are robust biomarkers of LRRK2 pathway activity in cells and biofluids (dzamko2025leucinerichrepeatkinase pages 2-4, lozano2024theroleofb pages 51-53, lozano2024theroleofa pages 51-53).
- Regulation: (i) 14‑3‑3 binding to the Ser910/Ser935 cluster is modulated by upstream kinases and disrupted by some PD‑linked LRRK2 variants; it provides a pharmacodynamic (PD) readout for inhibitors. (ii) Ser1292 autophosphorylation scales with pathogenic activation. (iii) Rab29-mediated recruitment/activation at the Golgi has been reported. (iv) Kinase↔GTPase cross‑talk within ROC‑COR‑kinase controls activity and oligomerization. (v) Redox-sensitive “CC” motif (C2024/C2025) in the activation segment modulates kinase activity and microtubule docking in response to oxidants/reductants (dzamko2025leucinerichrepeatkinase pages 9-10, gilsbach2024intramolecularfeedbackregulation pages 16-17).
- Cellular localization: LRRK2 is largely cytosolic but dynamically recruited to membranes where Rab substrates reside: Golgi, endosomes/lysosomes, and phagosomes. Under certain conditions and with specific inhibitor types, microtubule association and filament formation can occur, though endogenous detection varies across systems (dzamko2025leucinerichrepeatkinase pages 9-10, gilsbach2024intramolecularfeedbackregulation pages 16-17, dzamko2025leucinerichrepeatkinase pages 8-9).

Recent developments and latest research (emphasis 2023–2024)
- Intramolecular feedback and structural crosstalk: 2024 eLife work shows kinase-dependent phosphorylation of ROC (T1343) drives feedback on GTPase kinetics and monomer–dimer balance, advancing understanding of ROC–COR–kinase communication (Dec 2024; https://doi.org/10.7554/eLife.91083.4) (gilsbach2024intramolecularfeedbackregulation pages 16-17).
- Redox control of the kinase: 2024 NPJ Parkinson’s Disease identified a unique CC motif (C2024/C2025) in the activation segment that differentially contributes to catalysis (C2024 essential) and redox sensitivity (C2025), suggesting oxidative agents can downregulate hyperactive LRRK2 (Apr 2024; https://doi.org/10.1038/s41531-024-00683-5) (dzamko2025leucinerichrepeatkinase pages 9-10).
- Rab phosphorylation as core readout: Reviews and mechanistic syntheses reaffirm Rab10 Thr73 and other Rabs as endogenous substrates; phospho‑Rab immunoassays in immune cells are advancing to clinical PD biomarker use (Biochem J review, May 2025, references therein with earlier primary studies; https://doi.org/10.1042/BCJ20253099) (dzamko2025leucinerichrepeatkinase pages 2-4, dzamko2025leucinerichrepeatkinase pages 9-10).
- Ciliogenesis pathway: Rab8/Rab10 phosphorylation drives centrosomal cohesion and primary cilia deficits through RILPL1; this mechanistic axis continues to underpin cell‑type specific cilia phenotypes in disease models and patient cells (Human Mol Genet Aug 2019; https://doi.org/10.1093/hmg/ddz201; with 2023–2024 reviews expanding context) (ordonez2019rab8rab10and pages 32-33, lozano2024theroleofb pages 51-53).

Current applications and real‑world implementations
- Biomarkers: Peripheral immune-cell biomarkers include pRab10 Thr73 (typically measured in neutrophils/monocytes) and LRRK2 Ser935 phosphorylation; these show acceptable within‑subject variability and are used as PD biomarkers and for target engagement in early‑phase trials (Clinical & Translational Science May 2023; https://doi.org/10.1111/cts.13541; Biochem J May 2025; https://doi.org/10.1042/BCJ20253099) (dzamko2025leucinerichrepeatkinase pages 2-4). Autophosphorylation at Ser1292 has been detected in exosomes/CSF but is low abundance and technically challenging (dzamko2025leucinerichrepeatkinase pages 9-10).
- Drug development: Small‑molecule LRRK2 kinase inhibitors (e.g., type 1 ATP-competitive inhibitors including DNL151/BIIB122) have entered human studies; pSer935 and pRab10 serve as PD biomarkers for target engagement and dose–response (Biochem J review citing 2023–2024 clinical reports; https://doi.org/10.1042/BCJ20253099) (dzamko2025leucinerichrepeatkinase pages 8-9, dzamko2025leucinerichrepeatkinase pages 2-4). Type 2 inhibitors are being explored with distinct effects on pSer935 (dzamko2025leucinerichrepeatkinase pages 9-10).

Expert opinions and analysis from authoritative sources
- Dzamko 2025 review: Recommends multi‑matrix (blood/urine/CSF) biomarker panels that combine pRab10, pSer935, and downstream lysosomal readouts; emphasizes that most human studies to date are small and require multi‑site validation and longitudinal design (May 2025; https://doi.org/10.1042/BCJ20253099) (dzamko2025leucinerichrepeatkinase pages 8-9, dzamko2025leucinerichrepeatkinase pages 9-10).
- Mechanistic consensus: Rab GTPases are the principal substrates linking LRRK2 to endolysosomal trafficking and ciliogenesis; 14‑3‑3 binding to N‑terminal phosphosites stabilizes inactive conformations and is a reliable pharmacodynamic signal for type 1 inhibitors (dzamko2025leucinerichrepeatkinase pages 9-10, dzamko2025leucinerichrepeatkinase pages 2-4).

Relevant statistics and quantitative data
- Substrate breadth: Screens of 50 Rab proteins identified phosphorylation of 14 when overexpressed and evidence for at least 10 endogenous Rabs (including Rab8A/B, Rab10, Rab12, Rab29, Rab35, Rab43) as LRRK2 substrates (citations summarized in 2024 overview) (lozano2024theroleofa pages 51-53, lozano2024theroleof pages 51-53).
- Biomarker variability: Within‑subject geometric CVs across matrices ranged ~13–51% (whole blood/neutrophils) and higher in PBMCs (35–274%); between‑subject variability was lower in neutrophils/whole blood (45–123%) relative to PBMCs (190–415%) in a 2023 PD cohort (Clinical & Translational Science; https://doi.org/10.1111/cts.13541) (dzamko2025leucinerichrepeatkinase pages 2-4).

Functional roles, localization, and pathways
- Endolysosomal/Golgi trafficking: Pathogenic LRRK2 perturbs Golgi‑to‑lysosome traffic, retromer function (via Rab29), and lysosomal enzyme regulation (e.g., GCase), consistent with Rab substrate phosphorylation. LRRK2 concentrates at membranes of the endolysosomal system where these substrates reside (lozano2024theroleofb pages 51-53, lozano2024theroleofa pages 51-53, lozano2024theroleof pages 51-53).
- Ciliogenesis and centrosomal cohesion: LRRK2‑mediated phosphorylation of Rab8/Rab10 drives centrosomal accumulation and RILPL1‑dependent ciliogenesis defects; inhibition of LRRK2 rescues these phenotypes in cells and animal models (Human Mol Genet 2019; https://doi.org/10.1093/hmg/ddz201) (ordonez2019rab8rab10and pages 32-33).
- Biomarker and PD readouts: pRab10 (Thr73) in immune cells and pSer935 on LRRK2 are the most practical PD/TE biomarkers; Ser1292 autophosphorylation is informative but technically demanding (dzamko2025leucinerichrepeatkinase pages 2-4, dzamko2025leucinerichrepeatkinase pages 9-10).

Embedded quick‑reference artifact
| Category | Detail | Evidence/notes | Key recent sources (with DOI URLs) |
|---|---|---|---|
| Identity | Human LRRK2 — gene LRRK2; UniProt Q5S007; large multi‑domain ROCO family protein (aka dardarin/PARK8) | Identity and nomenclature confirmed across literature; widely studied in human Parkinson's disease context (lozano2024theroleof pages 51-53, gilsbach2024intramolecularfeedbackregulation pages 16-17) | Dzamko N. Biochem J. 2025. https://doi.org/10.1042/bcj20253099; Gilsbach et al., eLife 2024. https://doi.org/10.7554/eLife.91083.4 |
| Domain architecture | N‑terminal ARM/ANK/LRR repeats — ROC (GTPase) — COR tandem — Ser/Thr kinase domain — C‑terminal WD40 (ARM/ANK/LRR/ROC–COR–KIN–WD40) | Domain map from structural and biochemical studies; full‑length and domain structures document this organization (gilsbach2024intramolecularfeedbackregulation pages 16-17, lozano2024theroleofa pages 51-53) | Gilsbach et al., eLife 2024. https://doi.org/10.7554/eLife.91083.4; Myasnikov et al. (gilsbach2024intramolecularfeedbackregulation pages 16-17) |
| Catalytic activities | Dual enzymatic functions: Ser/Thr protein kinase (EC 2.7.11.1) and Roc GTPase (EC 3.6.5.-); intramolecular cross‑talk modulates activities | Dual activity and feedback between ROC–COR and kinase domains demonstrated biochemically and structurally (gilsbach2024intramolecularfeedbackregulation pages 16-17) | Gilsbach et al., eLife 2024. https://doi.org/10.7554/eLife.91083.4; (reviews collated in Dzamko 2025) https://doi.org/10.1042/bcj20253099 |
| Primary substrates | Selected physiologic substrates: Rab GTPases — Rab10 (Thr73), Rab8A/B, Rab12, Rab29, Rab35, Rab43 (phospho‑Rab readouts used as activity biomarkers) | Phosphoproteomics and targeted studies validated Rab10 Thr73 and multiple Rabs as direct LRRK2 kinase substrates (lozano2024theroleofb pages 51-53, lozano2024theroleofa pages 51-53, dzamko2025leucinerichrepeatkinase pages 2-4) | Ordóñez et al., Hum Mol Genet 2019. https://doi.org/10.1093/hmg/ddz201; Dzamko 2025. https://doi.org/10.1042/bcj20253099 |
| Regulatory mechanisms | 1) 14‑3‑3 binding regulated by N‑terminal phospho‑cluster (Ser910/Ser935/Ser955/Ser973); 2) Ser1292 autophosphorylation as activity marker; 3) Rab29 recruits/activates LRRK2 at Golgi; 4) ROC–COR–kinase intramolecular crosstalk; 5) redox-sensitive CC motif (C2024/C2025) modulates kinase/redox response | Multiple biochemical and structural reports document these controls and mutation effects on regulation (dzamko2025leucinerichrepeatkinase pages 9-10, gilsbach2024intramolecularfeedbackregulation pages 16-17, lozano2024theroleof pages 51-53) | Dzamko 2025. https://doi.org/10.1042/bcj20253099; Gilsbach et al., eLife 2024. https://doi.org/10.7554/eLife.91083.4; Trilling et al., NPJ PD 2024. https://doi.org/10.1038/s41531-024-00683-5 |
| Localization | Predominantly cytosolic but recruited to membranes (Golgi, endosomes/lysosomes, phagosomes); under some conditions associates with microtubules and forms filaments (not always detected at endogenous levels) | Cell and in situ structural/biochemical studies show dynamic cytosol↔membrane localization and stimulus‑dependent membrane recruitment (lozano2024theroleof pages 51-53, gilsbach2024intramolecularfeedbackregulation pages 16-17, dzamko2025leucinerichrepeatkinase pages 8-9) | Dzamko 2025. https://doi.org/10.1042/bcj20253099; Chen et al. (cryo‑ET studies cited in gathered evidence) https://doi.org/10.7554/eLife.100799 (dzamko2025leucinerichrepeatkinase pages 8-9) |
| Pathways / cellular roles | Endolysosomal and Golgi–lysosome trafficking, regulation of lysosomal homeostasis (LYTL — LRRK2‑driven lysosomal tubulation/sorting), ciliogenesis/centrosomal cohesion via phospho‑Rab10→RILPL1 axis, impacts on synaptic vesicle endocytosis and autophagy | Mechanistic links between Rab phosphorylation and disrupted trafficking/ciliogenesis/lysosomal function established in cellular, animal, and patient‑derived studies (ordonez2019rab8rab10and pages 32-33, lozano2024theroleofb pages 51-53, lozano2024theroleof pages 51-53) | Ordóñez et al., Hum Mol Genet 2019. https://doi.org/10.1093/hmg/ddz201; Bonet‑Ponce & Cookson reviews (lozano2024theroleof pages 51-53); Dzamko 2025. https://doi.org/10.1042/bcj20253099 |


*Table: Compact reference table summarizing human LRRK2 identity, domains, enzymatic activities, main substrates, regulation, localization and key pathways with evidence notes and recent DOI‑linked sources for rapid use in functional annotation and translational planning.*

URLs and publication dates (selected, recent/authoritative)
- Dzamko N (Review) “Leucine-rich repeat kinase 2 biomarkers for Parkinson’s disease.” Biochemical Journal, 482:709–720 (May 2025). URL: https://doi.org/10.1042/BCJ20253099 (supports biomarkers, regulation, translational context) (dzamko2025leucinerichrepeatkinase pages 9-10, dzamko2025leucinerichrepeatkinase pages 2-4, dzamko2025leucinerichrepeatkinase pages 8-9).
- Gilsbach BK et al. “Intramolecular feedback regulation of the LRRK2 Roc G domain by a LRRK2 kinase-dependent mechanism.” eLife (Dec 2024). URL: https://doi.org/10.7554/eLife.91083.4 (supports ROC–COR–kinase cross‑talk) (gilsbach2024intramolecularfeedbackregulation pages 16-17).
- Trilling CR et al. “RedOx regulation of LRRK2 kinase activity by active site cysteines.” NPJ Parkinson’s Disease 10 (Apr 2024). URL: https://doi.org/10.1038/s41531-024-00683-5 (supports redox CC motif) (dzamko2025leucinerichrepeatkinase pages 9-10).
- Ordóñez AJL et al. “RAB8, RAB10 and RILPL1 contribute to both LRRK2 kinase–mediated centrosomal cohesion and ciliogenesis deficits.” Human Molecular Genetics 28:3552–3568 (Aug 2019). URL: https://doi.org/10.1093/hmg/ddz201 (mechanistic pathway for ciliogenesis/cilia loss) (ordonez2019rab8rab10and pages 32-33).
- Lozano MR (2024 synopsis). “The role of RAB10 and RAB29 in endolysosomal trafficking alterations mediated by pathogenic LRRK2.” (2024). Evidence compiled on Rab substrates, 14‑3‑3 regulation, Golgi/lysosome trafficking (lozano2024theroleofb pages 51-53, lozano2024theroleofa pages 51-53, lozano2024theroleof pages 51-53).
- Vissers MFJM et al. “LRRK2 pathway biomarker characterization study…” Clinical and Translational Science 16:1408–1420 (May 2023). URL: https://doi.org/10.1111/cts.13541 (biomarker variability across matrices) (dzamko2025leucinerichrepeatkinase pages 2-4).

Conclusion
- The human LRRK2 protein (Q5S007) is a dual‑enzyme ROCO protein that phosphorylates a defined subset of Rab GTPases, coupling cytosolic→membrane localization to control endolysosomal and Golgi–lysosome trafficking and ciliogenesis. Regulation integrates 14‑3‑3 binding at N‑terminal phosphosites, autophosphorylation, Rab29‑mediated recruitment, redox‑sensitive residues, and ROC–COR–kinase domain cross‑talk. Translationally, pRab10 and pSer935 are practical biomarkers for pathway activity and target engagement; type‑1 LRRK2 inhibitors have advanced into early clinical testing with these pharmacodynamic readouts. Larger, multi‑site human studies are a current need to validate biomarker–disease relationships and optimize trial design (dzamko2025leucinerichrepeatkinase pages 9-10, dzamko2025leucinerichrepeatkinase pages 2-4, dzamko2025leucinerichrepeatkinase pages 8-9).

References

1. (gilsbach2024intramolecularfeedbackregulation pages 16-17): Bernd K Gilsbach, Franz Y Ho, Benjamin Riebenbauer, Xiaojuan Zhang, Giambattista Guaitoli, Arjan Kortholt, and Christian Johannes Gloeckner. Intramolecular feedback regulation of the lrrk2 roc g domain by a lrrk2 kinase-dependent mechanism. eLife, Dec 2024. URL: https://doi.org/10.7554/elife.91083.4, doi:10.7554/elife.91083.4. This article has 5 citations and is from a domain leading peer-reviewed journal.

2. (dzamko2025leucinerichrepeatkinase pages 9-10): Nicolas Dzamko. Leucine-rich repeat kinase 2 biomarkers for parkinson’s disease. Biochemical Journal, 482:709-720, May 2025. URL: https://doi.org/10.1042/bcj20253099, doi:10.1042/bcj20253099. This article has 2 citations and is from a domain leading peer-reviewed journal.

3. (dzamko2025leucinerichrepeatkinase pages 2-4): Nicolas Dzamko. Leucine-rich repeat kinase 2 biomarkers for parkinson’s disease. Biochemical Journal, 482:709-720, May 2025. URL: https://doi.org/10.1042/bcj20253099, doi:10.1042/bcj20253099. This article has 2 citations and is from a domain leading peer-reviewed journal.

4. (lozano2024theroleofb pages 51-53): M Romo Lozano. The role of rab10 and rab29 in endolysosomal trafficking alterations mediated by pathogenic lrrk2. Unknown journal, 2024.

5. (lozano2024theroleofa pages 51-53): M Romo Lozano. The role of rab10 and rab29 in endolysosomal trafficking alterations mediated by pathogenic lrrk2. Unknown journal, 2024.

6. (dzamko2025leucinerichrepeatkinase pages 8-9): Nicolas Dzamko. Leucine-rich repeat kinase 2 biomarkers for parkinson’s disease. Biochemical Journal, 482:709-720, May 2025. URL: https://doi.org/10.1042/bcj20253099, doi:10.1042/bcj20253099. This article has 2 citations and is from a domain leading peer-reviewed journal.

7. (ordonez2019rab8rab10and pages 32-33): Antonio Jesús Lara Ordónez, Belén Fernández, Elena Fdez, María Romo-Lozano, Jesús Madero-Pérez, Evy Lobbestael, Veerle Baekelandt, Ana Aiastui, Adolfo López de Munaín, Heather L Melrose, Laura Civiero, and Sabine Hilfiker. Rab8, rab10 and rilpl1 contribute to both lrrk2 kinase–mediated centrosomal cohesion and ciliogenesis deficits. Human Molecular Genetics, 28:3552-3568, Aug 2019. URL: https://doi.org/10.1093/hmg/ddz201, doi:10.1093/hmg/ddz201. This article has 90 citations and is from a domain leading peer-reviewed journal.

8. (lozano2024theroleof pages 51-53): M Romo Lozano. The role of rab10 and rab29 in endolysosomal trafficking alterations mediated by pathogenic lrrk2. Unknown journal, 2024.

## Citations

1. gilsbach2024intramolecularfeedbackregulation pages 16-17
2. dzamko2025leucinerichrepeatkinase pages 9-10
3. dzamko2025leucinerichrepeatkinase pages 2-4
4. dzamko2025leucinerichrepeatkinase pages 8-9
5. lozano2024theroleof pages 51-53
6. lozano2024theroleofb pages 51-53
7. lozano2024theroleofa pages 51-53
8. https://doi.org/10.7554/eLife.91083.4
9. https://doi.org/10.1038/s41531-024-00683-5
10. https://doi.org/10.1042/BCJ20253099
11. https://doi.org/10.1093/hmg/ddz201;
12. https://doi.org/10.1111/cts.13541;
13. https://doi.org/10.1111/cts.13541
14. https://doi.org/10.1093/hmg/ddz201
15. https://doi.org/10.1042/bcj20253099;
16. https://doi.org/10.7554/eLife.91083.4;
17. https://doi.org/10.1042/bcj20253099
18. https://doi.org/10.7554/eLife.100799
19. https://doi.org/10.7554/elife.91083.4,
20. https://doi.org/10.1042/bcj20253099,
21. https://doi.org/10.1093/hmg/ddz201,